-
公开(公告)号：EP2942082B1
公开(公告)日：2019-03-06
申请号：EP15165962.0
申请日：2003-01-28
发明人： Kase, Hiroshi , Mori, Akihisa , Waki, Yutaka , Ohsawa, Yutaka , Karasawa, Akira , Kuwana, Yoshihisa
IPC分类号： A61P25/16 , A61P25/14 , A61K31/522 , A61K45/06 , A61K31/198
-
2.发明公开
公开(公告)号：EP2942082A3
公开(公告)日：2016-01-27
申请号：EP15165962.0
申请日：2003-01-28
发明人： Kase, Hiroshi , Mori, Akihisa , Waki, Yutaka , Ohsawa, Yutaka , Karasawa, Akira , Kuwana, Yoshihisa
IPC分类号： A61P25/16 , A61P25/14 , A61K31/522 , A61K45/06
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A 2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A 2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A 2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A 2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
-
3.发明公开
公开(公告)号：EP2942082A2
公开(公告)日：2015-11-11
申请号：EP15165962.0
申请日：2003-01-28
发明人： Kase, Hiroshi , Mori, Akihisa , Waki, Yutaka , Ohsawa, Yutaka , Karasawa, Akira , Kuwana, Yoshihisa
IPC分类号： A61P25/16 , A61P25/14 , A61K31/522 , A61K45/06
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A 2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A 2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A 2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A 2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
-
公开(公告)号：EP2260850B1
公开(公告)日：2018-07-04
申请号：EP10179406.3
申请日：2003-01-28
发明人： Kase, Hiroshi , Mori, Akihisa , Waki, Yutaka , Ohsawa, Yutaka , Karasawa, Akira , Kuwana, Yoshihisa
IPC分类号： A61K31/522 , A61P25/16 , A61P25/14 , A61K31/198 , A61K45/06
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A 2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A 2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A 2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A 2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
-
5.发明公开A2A receptor antogonists for use in the treatment of movement disorders 有权A2A Rezeptor Antagonisten zur Verwendung in der Behandlung vonBewegungsstörungen
公开(公告)号：EP2260850A3
公开(公告)日：2013-11-13
申请号：EP10179406.3
申请日：2003-01-28
发明人： Kase, Hiroshi , Mori, Akihisa , Waki, Yutaka , Ohsawa, Yutaka , Karasawa, Akira , Kuwana, Yoshihisa
IPC分类号： A61K31/522 , A61P25/16 , A61P25/14
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A 2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A 2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A 2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A 2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
摘要翻译： 本发明涉及通过向有需要的患者施用有效量的一种或多种腺苷A 2A受体拮抗剂来治疗运动障碍的方法。 本发明还提供降低L-DOPA在接受L-DOPA治疗的帕金森病治疗中的不良反应的方法。 本发明还提供了通过将L-DOPA治疗与有效量的一种或多种腺苷A 2A受体拮抗剂组合（即，L-DOPA备用效应）来治疗帕金森病患者的亚临床有效剂量的L-DOPA的方法和组合物 ）。 本发明还提供了通过共同施用至少一种腺苷A 2A受体拮抗剂，L-DOPA和多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂来有效治疗帕金森病的方法。 本发明还提供了延长帕金森病有效治疗的方法，其通过单独给予腺苷A 2A受体拮抗剂或与多巴胺激动剂和/或COMT抑制剂和/或MAO抑制剂一起施用， DOPA，延迟或去除L-DOPA电机并发症。
-
6.发明公开
公开(公告)号：EP2260850A2
公开(公告)日：2010-12-15
申请号：EP10179406.3
申请日：2003-01-28
发明人： Kase, Hiroshi , Mori, Akihisa , Waki, Yutaka , Ohsawa, Yutaka , Karasawa, Akira , Kuwana, Yoshihisa
IPC分类号： A61K31/522 , A61P25/16
CPC分类号： A61K31/522 , A61K9/0019 , A61K9/20 , A61K9/48 , A61K31/198 , A61K45/06
摘要： The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A 2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A 2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A 2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A 2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.011 秒)
